A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this prospectively randomized multicentre study was to prove the efficacy and
safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear
graft survival following high-risk keratoplasty.
The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were
immune reaction free and clear graft survival and the occurence of side-effects.